Introduction
============

DNA transcription depends on the availability of pyrimidine (UTP and CTP) and purine (GTP and ATP) ribonucleoside triphosphate substrates, and their *de novo* synthesis is subjected to tight homoeostatic controls. In yeast, the first two steps of UTP biosynthesis are catalysed by Ura2, a bifunctional protein endowed with carbamoyl phosphate synthetase and aspartate transcarbamoylase activities ([@b29]). These are the main rate-limiting steps of the pathway, and their allosteric control by UTP is well documented ([@b21]; [@b32]). Similar to other genes of the UTP biosynthetic pathway, *URA2* transcription is induced in the presence of 6-azauracil, which depletes cells in UTP ([@b9]). A previous study ([@b24]) has suggested that this does not depend on Ppr1, a transcriptional activator specific for the pyrimidine biosynthetic pathway ([@b23]; [@b24]; [@b10]), as *ppr1-2*, a mutation unable to activate *URA1* or *URA3*, had no effect on Ura2 activity in cell-free extracts. Moreover, we here show that a *ppr1*Δ null allele remains fully competent for *URA2* transcription.

In this study, two classes of mutations were found to constitutively activate *pURA2∷HIS3* or *pURA2∷LacZ* reporter plasmids. The first class was due to short deletions immediately upstream of the *URA2* mRNA 5′-ends, indicating that this region acts as negative regulatory element of *URA2* transcription. A second class altered *RPB1*, which encodes the largest subunit of RNA polymerase II, and specifically modified the Switch 1 loop of the active site. One of these mutations, *rpb1-L1397S*, was investigated in more detail. It showed a genome-wide reduced occupancy of RNA polymerase II, consistent with its partial growth defect, but specifically activated *URA2, IMD2/IMD3* and *URA8* (encoding rate-limiting steps of the UTP, GTP and CTP biosynthetic pathways, respectively), thus raising the intriguing possibility that the Switch 1 loop of RNA polymerase II might act as a sensor of nucleoside triphosphate depletion.

Results
=======

UTP depletion activates URA2 independently of the Ppr1 activator
----------------------------------------------------------------

The *URA2* open reading frame is separated by 1231 nt from the stop codon of the upstream gene *TRK1* ([Figure 1A](#f1){ref-type="fig"}). A *Kpn*I--*Bam*HI cassette bearing this DNA was cloned in frame with the *LacZ* or *HIS3* open reading frames, generating the *pURA2∷LacZ* reporter plasmids pFL80 and pFL80-H2, and the *pURA2∷HIS3* reporter pFL81 (Materials and methods). There was a fivefold *LacZ* activation in wild-type cells grown under repressing (uracil) or derepressing (6-azauracil) conditions ([Figure 1B](#f1){ref-type="fig"}), and a similar range of activation was observed in the steady-state level of *URA2* mRNAs ([Figure 1C](#f1){ref-type="fig"}), indicating that the *pURA2∷LacZ* reporter correctly reflects the transcriptional regulation of *URA2*.

Adding 6-azauracil blocks UTP synthesis and also reduces the cellular pool of GTP ([@b9]). However, no *pURA2∷LacZ* activation was observed in the presence of mycophenolate, which specifically blocks IMP dehydrogenase ([@b33]), and thus only depletes GTP. Likewise, counteracting GTP inhibition by adding guanine to the CSM+6AU medium did not reduce the activating effect of 6-azauracil (data not shown). Finally, impairing the metabolic conversion of UTP to CTP in temperature-sensitive mutant (*ura8-ts ura7*Δ) reduced the expression of *pURA2∷LacZ*, which presumably reflects the accumulation of UTP under these conditions and implies that *URA2* does not respond to CTP shortage. These data indicated that *URA2* transcription is primarily activated by a shortage in UTP, with little or no effect of GTP or CTP.

Other genes of the pyrimidine pathway, such as *URA1* and *URA3*, are also derepressed under UTP depletion, and their activation is lost in *ppr1-2*, a mutation that alters the Ppr1 activator but has no effect on the Ura2 activity in cell-free extracts ([@b24]). Consistent with this observation, we found here that the *ppr1*Δ null allele strongly reduced the activation of *URA1* and *URA3* in the presence of 6-azauracil, as measured by RT--PCR quantification of their mRNAs and by their RNA polymerase II occupancy in chromatin-immunoprecipitation (ChIP) assays (shown in [Figure 1C](#f1){ref-type="fig"} for the *URA1* gene). In contrast, *ppr1*Δ actually increased the level of *URA2* mRNA produced in the presence of 6-azauracil, which may reflect a particularly effective depletion in UTP, due to its inability to activate *URA1* and *URA3*.

Organisation of the URA2 promoter region
----------------------------------------

It was previously thought that *URA2* transcription starts some 70 nt ahead of the ATG start codon ([@b28]). This is clearly inconsistent with the recent report of an untranslated intron between positions −385 and −66 relatively to the ATG ([@b18]). As shown in [Figure 2](#f2){ref-type="fig"}, we confirmed the existence of this intron, although with different 3′-ends corresponding to positions −63, −54 or, in one case, +12. The corresponding DNA has a 5′-end consensus (~−384~GUAUGU~−379~), a canonical branch point box (~−92~UACUAAC~−84~), and a ~−68~UAG~−65~ at the 3′-splice site. An intron deletion did not detectably affect the expression of *pURA2∷LacZ* (bottom line of [Figure 2A](#f2){ref-type="fig"}).

Using RNA ligase mediated-RACE assays, we obtained and sequenced 13 cDNAs that, by construction, extended to position +188 of the *URA2* open reading frame and thus corresponded to the 5′-end domains of full-length mRNAs ([Figure 2B](#f2){ref-type="fig"}). These 5′-ends defined six positions (−588A, −579T, −576A, −571A, −565A and −563A) clustered within an A-rich domain, matching to the initiator consensus (A~rich~)~5~N(C/T)[A]{.ul}(A/T)NN(A~rich~)~6~ deduced from a recent survey of yeast mRNAs ([@b44]). A parallel study ([@b37]) has identified a second initiator region (positions −686/−657, denoted by a grey arrow in [Figure 2A](#f2){ref-type="fig"}) upstream of the one shown here to be used for full-length *URA2* mRNAs. This upstream initiator produces short unstable non-coding RNAs with the same transcriptional orientation as *URA*2. It is evidently not used to produce full-length *URA2* transcripts, as the predicted 5′-ends were not found in the corresponding cDNAs ([Figure 2B](#f2){ref-type="fig"}). Five TCTT (UCUU) boxes, present immediately upstream of the *URA2* initiator, form a cluster of binding sites recognised by Nab3, which belongs to the transcriptional terminator system operating on non-coding intergenic RNAs ([@b1]; [@b38]).

The DNA upstream of the URA2 initiator prevents the progression of RNA polymerase II
------------------------------------------------------------------------------------

Partial deletions of the *TRK1-URA2* intergenic region were introduced in *pURA2∷LacZ* reporters (pFL80 and pFL80-H2) and tested for *LacZ* activation under repressing (uracil) and derepressing (6-azauracil) conditions. Deleting the first 297 nt had no effect on *pURA2∷LacZ*, but a *Bsr*GI/*Sal*I deletion lacking positions −934/−580 almost entirely blocked *pURA2∷LacZ* expression ([Figure 2A](#f2){ref-type="fig"}). The corresponding DNA is therefore critical for *URA2* transcription. It contains a TATAAA box (−776/−771) shown by [@b37] to be needed for the synthesis of the *URA2* mRNA and of its short-lived upstream transcripts.

The *Bsr*GI/*Sal*I DNA was submitted to error-prone amplification and recombined into the *pURA2∷HIS3* reporter (pFL83), producing plasmids that were selected for *HIS3* overexpression in the presence of uracil. No single-base mutation was isolated by this approach, but we obtained three very similar deletions *up2*Δ (−647/−577), *up6*Δ (−634/−579) or *up10*Δ (−650/−579) upstream of the *Sal*I site ([Figure 3A](#f3){ref-type="fig"}). These deletions overexpressed *LacZ* when subcloned into *pURA2∷LacZ* reporters (pFL80-H2 and pFL80), and a chromosomal *up2*Δ mutant (FL51) constitutively expressed the *URA2* mRNA under-repressing conditions ([Figure 3B](#f3){ref-type="fig"}). Moreover, *up2*Δ only acted in *cis*, as the promoter reporter (*pURA2∷LacZ*) was not activated in the *up2*Δ host (data not shown).

The ChIP assays of [Figure 4A](#f4){ref-type="fig"} show that the region upstream of the *URA2* start site is occupied by TFIIB and TFIIH, two components of the RNA polymerase II pre-initiation complex. The corresponding RNA polymerase II signal was recognised by anti-CTD antibodies, and also by an anti-Rpb3∷HA tag (see Figure 7D below), but not by antibodies raised against Ser2-phosphorylated CTD ([Figure 4B](#f4){ref-type="fig"}). The CTD-Ser2^P^ signal was only detected downstream of the *URA2* initiator region. As shown in [Figure 4C](#f4){ref-type="fig"}, this also coincided with a drop in RNA polymerase II occupancy, observed in wild-type or *ppr1*Δ cells grown under repressing conditions.

*URA2* activation in wild-type or *ppr1*Δ cells exposed to 6-azauracil did not increase the RNA polymerase II signal detected upstream of the initiator region, but correlated with a full occupancy of the *URA2* open reading frame by RNA polymerase II ([Figure 4C](#f4){ref-type="fig"}). Likewise, the *up2*Δ mutation produced a strong RNA polymerase II signal downstream of the initiator, even when grown under repressive conditions ([Figure 4C](#f4){ref-type="fig"}). Thus, *URA2* activation is not due to an increased recruitment of RNA polymerase II (as in the case of Ppr1-dependent genes such as *URA1*; see [Figure 1C](#f1){ref-type="fig"}) but results from an extended RNA polymerase II occupancy downstream of the *URA2* initiator region. Moreover, a relatively short DNA region, lost in *up2*Δ and located immediately upstream of the *URA2* initiator, impairs *URA2* transcription by preventing RNA polymerase II from progressing towards the *URA2* open reading frame.

Mutants of the RNA polymerase II Switch 1 loop activate URA2 expression
-----------------------------------------------------------------------

To search for *trans*-acting regulator(s) of *URA2*, mutations constitutively expressing the chromosomal *pURA2∷HIS3* reporter of strain FL52 were selected after UV mutagenesis. We obtained four mutants (FL-M9, M10, M13 and M23) that were resistant to 3-aminotriazol on uracil-supplemented medium and also overexpressed the *pURA2∷LacZ* reporter. They grew slowly at 30 °C, failed to grow at 16 °C and 37 °C and were somewhat sensitive to 6-azauracil (shown in [Figure 5A](#f5){ref-type="fig"} for the FL-M9 strain). Meiotic tetrad analysis showed that these phenotypes co-segregated in a monogenic and recessive way, and complementation tests established that the corresponding mutations belonged to one and the same gene.

We then transformed FL-M9 with a yeast genomic library and obtained one plasmid restoring growth at 37 °C. The corresponding insert harboured *RPB1*, which encodes the largest subunit of RNA polymerase II, and three surrounding genes. Further subcloning showed that growth at 37 °C correlated with an intact *RPB1* gene, and complementation tests with the temperature-sensitive allele *rpb1-1* ([@b31]) firmly established that all four mutants were due to *rpb1* mutations. *In vivo* gap repair ([@b30]) indicated that these mutations belonged to the *Swa*I--*Psh*AI segment of *RPB1*. Finally, DNA sequencing revealed single amino-acid replacements corresponding to *rpb1-L1397S* (M9), *rpb1-S1401P* (M10) and *rpb1-F1402L* (M13 and M23), which were also present in the chromosomal DNA of the original mutant strains.

The above-mentioned data led to the rather unexpected conclusion that *URA2* activation occurs by *trans*-acting mutations altering RNA polymerase II itself, at the level of its Switch 1 loop fold. RT--PCR and *LacZ* assays confirmed that *rpb1-L1397S* highly expressed *URA2* ([Figure 5B and C](#f5){ref-type="fig"}). Moreover, an *rpb1-L1397S up2*Δ double-mutant had the same constitutive expression as *up2*Δ alone, and a *pURA2∷LacZ* reporter bearing the *up2*Δ allele (plasmid pFL80-up2Δ) was expressed at the same level when tested in wild-type or in an *rpb1-L1397S* host strain ([Figure 5B and C](#f5){ref-type="fig"}). In other words, *rpb1-L1397S* and *up2*Δ have epistatic effects on *URA2* expression, thus strongly suggesting that they are defective in the same mechanism downregulating *URA2* in response to uracil.

The six amino-acid segment occupied by L1397, S1401 and F1402 corresponds to Rpb1-α47b, one of the two α helices forming the Switch 1 loop domain of the RNA polymerase II active site ([@b12]). Moreover, the *rpb1-G1388V* allele, altering the Rpb1-α47a helix ([@b3]), also resulted in a high constitutive expression of *URA2* (data not shown). This high clustering was not anticipated in a UV mutagenesis, as the latter evidently affects the whole yeast genome. Our genetic screen was presumably not saturating, and we cannot exclude that *URA2* activation may, for some reason, be a general property of partly defective RNA polymerase II mutants. We thus tested the *pURA2∷LacZ* reporter (pFL80) in 10 other slow-growing mutations partly impairing Rpb1 (*rpb1-G1437D*, *rpb1-E1351K* and *rpb1-H1367D*) or Rpb2 (*rpb2-R857K*, *rpb2-E836A*, *rpb2-D978A, rpb2-P1018S* and *rpb2-G1142D*) or lacking the non-essential subunits Rpb4 (*rpb4*Δ) or Rpb9 (*rpb9*Δ) ([@b42]; [@b31]; [@b41]). Except for a modest derepressing effect of *rpb2-E836A* and *rpb2-R857K*, their β-galactosidase activity was equal to or lower than the wild-type control (data not shown), thus strongly suggesting that *URA2* activation, at least to a large extent, is primarily due to changes in the Switch 1 loop.

The Switch1 loop is highly conserved in all eukaryotic and archaeal RNA polymerases ([Figure 6A](#f6){ref-type="fig"}). Together with the α25 Bridge helix, α36 Trigger helix and the α46/47 Loop of Rpb1, it forms an identical fold in the RNA polymerase of *Sulfolobus solfataricus* ([@b15]) and in yeast RNA polymerase II ([@b12]). This fold wraps the downstream end of the transcription bubble and holds the DNA template strand by the invariant R1386-E1403 Switch 1 dipole ([Figure 6B and C](#f6){ref-type="fig"}). As discussed elsewhere ([@b43]), this fold is stabilised by the C-end of the Rpb5 subunit, itself strongly conserved from archaea to eukaryotes. Bacterial RNA polymerases, on the other hand, have no Rpb5 and their Switch 1 loop is considerably extended but nevertheless adopts a very similar spatial orientation ([@b39]).

rpb1-L1397S enhances RNA polymerase II occupancy downstream of the URA2 initiator
---------------------------------------------------------------------------------

Consistent with the partial growth defects of *rpb1-L1397S*, a twofold reduction in RNA polymerase II occupancy was seen for *rpb1-L1397S* in single-gene ChIP assays at *ADH1* or *PYK1* ([Figure 7A](#f7){ref-type="fig"}). This extended to the whole genome, with an average occupancy level of 62% (*R*^2^=0.80) relatively to wild type ([Figure 7B](#f7){ref-type="fig"}). As expected, RNA polymerase II occupancy was increased on the *URA2* open reading frame. Moreover, this increased occupancy was only seen downstream of the *URA2* initiator region ([Figure 7C](#f7){ref-type="fig"}). Similar results were obtained in ChIP assays done in *RPB3∷3HA rpb1-L1397S* cells, showing that this effect is independent of the precipitating antigen ([Figure 7D](#f7){ref-type="fig"}). In contrast, two RNA polymerase II alleles (*rpb2-P1018S* and *rpb9*Δ) with partial growth defects similar to those of *rpb1-L1397S* significantly reduced RNA polymerase II signal, upstream and downstream of the initiator region. Taken together, these data clearly show that *rpb1-L1397S* activates *URA2* by extending RNA polymerase II occupancy downstream of the initiator region, thus recapitulating the effect seen above for *up2*Δ or for wild-type and *ppr1*Δ cells exposed to 6-azauracil.

rpb1-L1397S extends RNA polymerase II downstream of IMD2, IMD3 and URA8
-----------------------------------------------------------------------

We have seen above that *rpb1-L1397S* generally reduced RNA polymerase II occupancy, except for *URA2*. This was also consistent with genome-wide transcriptome assays, showing a moderate but significant overexpression of *URA2* in *rpb1-L1397S*, compared with an isogenic wild-type control ([Figure 8A](#f8){ref-type="fig"}). Furthermore, these transcriptome and genome-wide RNA polymerase II occupancy assays identified two other genes, *IMD2* (IMP dehydrogenase) and *URA8* (CTP synthase), which were both overexpressed and over-occupied by RNA polymerase II in *rpb1-L1397S*. A few additional genes were also overexpressed in the *rpb1-L1397S* transcriptome, but with no higher RNA polymerase II occupancy of their open reading frames (data not shown). Conversely, *rpb1-L1397S* enhanced RNA polymerase II at *ADE12* (adenylosucinate synthase), but had no detectable effect on its mRNA level.

*Saccharomyces cerevisiae* has two CTP synthases (*URA7* and *URA8*) and three active IMP dehydrogenase genes (*IMD2*, *IMD3* and *IMD4*), with *IMD1* as a pseudo-gene inactivated by a frame-shift mutation in most laboratory strains ([@b27]; [@b26]; [@b16]). *URA7* and *URA8* are sufficiently different to be distinguished by individual RT--PCR assays, which clearly showed that *rpb1-L1397S* activated only *URA8* ([Figure 8B](#f8){ref-type="fig"}). RT--PCR assays also confirmed the overexpression of the IMP dehydrogenase mRNA in *rpb1-L1397S* but did not clearly distinguish between *IMD2*, *IMD3* and *IMD4*, due to their very similar nucleotide sequences. However, our genome-wide ChIP assays readily discriminated between these three genes. This revealed that *rpb1-L1397S* strongly activated *IMD2*, with some effect on *IMD3* ([Figure 8C](#f8){ref-type="fig"}) and no effect at all on *IMD4* (not shown). We considered the possibility that the activation of CTP synthase and IMP dehydrogenase genes may be an indirect effect of *URA2* overexpression, reflecting an increased cellular pool of UTP. However, the activation of *URA2* in *up2*Δ was not accompanied by a parallel increase in *URA8* or IMP dehydrogenase mRNA, thus strongly arguing for a direct activating effect of *rpb1-L1397S* ([Figure 8B](#f8){ref-type="fig"}).

Previous studies have shown that *IMD2* is controlled by an initiation switch between short transcripts, synthesised from an upstream initiator, and full-length mRNAs starting from a downstream initiator ([@b8]; [@b36]; [@b20]; [@b17]). RNA polymerase II is confined to the upstream initiator when wild-type cells are grown under repressing conditions ([@b36]), but extended to the entire *IMD2* gene in *rpb1-L1397S* or in derepressed wild-type cells that have been exposed to mycophenolate ([Figure 8C](#f8){ref-type="fig"}). In *URA8* and perhaps in *ADE12*, [@b37] have provided evidence for a transcriptional switch reminiscent of the *IMD2* case. Again, RNA polymerase II was mostly restricted to the upstream part of the gene in wild-type cells grown under repressing conditions, but extended to the entire *URA8* open reading frame in *rpb1-L1397S* ([Figure 8C](#f8){ref-type="fig"}). A similar effect may apply to *ADE12*, encoding the first step of the ATP biosynthetic pathway, where *rpb1-L1397S* moderately increased RNA polymerase II occupancy downstream of the promoter region ([Figure 8D](#f8){ref-type="fig"}).

Discussion
==========

Previous studies have shown that *URA1* or *URA3* are specifically activated by Ppr1, a Zn activator of the Gal4-type which responds to increased concentration of the orotate and/or dihydro-orotate precursors of UTP ([@b23]; [@b24]; [@b10]). This leads to an increased RNA polymerase II occupancy at the *URA1* and *URA3* promoters, lost in the *ppr1*Δ-null allele, indicating a 'classical\' mode of gene-specific activation on the basis of a more effective recruitment of RNA polymerase II by its pre-initiation complex. *URA2*, which encodes the main rate-limiting enzyme of UTP biosynthesis, is activated when UTP is depleted by 6-azauracil addition. However, the *ppr1*Δ-null allele is fully competent for *URA2* transcription. Moreover, and in contrast to *URA1* or *URA3*, *URA2* activation does not change the amount of RNA polymerase II residing at or upstream of the *URA2* initiator region, but operates instead by extending RNA polymerase II occupancy to the *URA2* open reading frame.

Three *cis*-acting mutations constitutively expressing *URA2* were selected in this study. They corresponded to very similar deletions (*up2*Δ, *up6*Δ and *up10*Δ) removing a 55--70 nt DNA region upstream of the *URA2* initiator. The *up2*Δ mutation was studied in more detail. It extended RNA polymerase II to the entire *URA2* open reading frame, with no change in the RNA polymerase II signal upstream of the *URA2* initiator, thus recapitulating the pattern seen in UTP-depleted wild-type or *ppr1*Δ cells. Further studies ([@b37]) have shown that the corresponding DNA is transcribed from an initiator region located some 100 nt upstream of the main *URA2* mRNA 5′-ends identified here, producing unstable RNAs with the same transcriptional orientation as *URA2*, which were no longer detected in *up2*Δ. Taken together, these data suggest that *URA2* may be regulated by an attenuation mechanism related to the one recently described for *IMD2* ([@b8]; [@b7]; [@b36]; [@b20]; [@b17]).

A genome-wide selection for *trans*-acting mutations constitutively expressing *URA2* yielded three tightly clustered *rpb1* mutations (*rpb1-L1397S*, *rpb1-S1401P* and *rpb1-F1402L*), corresponding to the Rpb1α-47b helix of the Switch 1 loop. *rpb1-G1388V*, which was initially selected for its ability to alter transcription initiation in favour of downstream sites ([@b3]) and belongs to the Rpb1-α47a helix, also activates *URA2* (see also [@b37]). In contrast, other partly defective RNA polymerase II mutations failed to derepress *URA2*, indicating that *URA2* activation is by no means a general property of RNA polymerase II mutants. Similar to *up2*Δ, *rpb1-L1397S* activates *URA2* by extending RNA polymerase II occupancy to the entire open reading frame, with no change in the signal upstream of the *URA2* initiator, thereby reproducing the effect seen in *up2*Δ and in UTP-depleted wild-type cells. Moreover, *up2*Δ and *rpb1-L1397S* had epistatic effects on *URA2* expression, indicating that *rpb1-L1397S* is defective in the attenuation mechanism lost in *up2*Δ itself. Finally, *rpb1-L1397S* and wild-type *URA2* mRNAs had similar 5′-ends, as determined by 5′-RACE assays, and therefore use the same transcription initiator.

The above-mentioned data indicate that changes in the Switch 1 loop specifically activate *URA2*, despite their adverse effects on growth and their reduced genome-wide RNA polymerase II occupancy. Moreover, we were unable to identify mutants encoding a specific regulator of *URA2*, although it remained possible that such mutants are lethal because they perturb some essential cellular process. The Switch 1 loop forms an invariant R1386(α47a)-E1403(α47b) dipole, holding the DNA template strand at positions +2/+3 downstream of the catalytic Mg^2+^ ([@b12]). This domain is highly conserved among eukaryotic and archaeal RNA polymerases ([@b6]; [@b15]) and a related structure exists in the bacterial enzyme, where it also binds DNA at positions +2/+3 downstream of the catalytic Mg^2+^ ([@b39]; [@b43]).

The relation of this domain to the entry route of NTPs in RNA polymerase II is unclear ([@b22]). One possibility is that NTPs reach the catalytic site of RNA polymerase II by its funnel-shaped pore ([@b6]; [@b19]; [@b40]; [@b22]), but it has also been suggested that NTPs enter through the large DNA channel, transiently binding the DNA template at nucleotides +2, +3 and possibly +4 ([@b13]), which implies that NTPs pass by the Switch 1 loop before reaching the catalytic Mg^2+^. Hence, the Switch 1 loop may act as an NTP-sensing module, enabling RNA polymerase II to adopt a processive mode of elongation when enough NTP is available. This would optimise the efficiency of transcription, which may account for the cold- and heat-sensitive defects of *rpb1-L1397S*, *rpb1-S1401P* and *rpb1-F1402L* and their increased sensitivity to 6-azauracil and mycophenolate.

Strikingly, *rpb1-L1397S* also extended RNA polymerase II occupancy downstream of the *IMD2/IMD3* (IMP dehydrogenase) and *URA8* (CTP synthase) promoters, with some evidence for a similar effect on *ADE12* (adenylosuccinate synthase). This makes biological sense, as the corresponding genes encode rate-limiting enzymes in the *de novo* synthesis of GTP, CTP and ATP. This suggests the rather non-canonical view that nucleoside triphosphate shortage or RNA polymerase II Switch 1 loop mutations (assumed here to mimic that shortage) specifically activate the expression of genes that are themselves critical for the *de novo* synthesis of NTPs. In other words, the transcriptional response to NTP shortage would not rely on dedicated activators or repressors (which have been vainly searched for in the case of *URA2* and *IMD2*) but would be mediated by an NTP-sensing mechanism built in the structure of RNA polymerase II itself.

In *IMD2*, there is good evidence that RNA polymerase II molecules are recruited on a common pre-initiation complex, followed by a start site switch leading to the alternative production of upstream transcripts ended by Nab3/Nrd1-dependent termination or full-length mRNAs transcribed from a downstream initiator region. Start site selection is presumably dictated by the nucleotide composition of the surrounding DNA, with upstream transcription starting at Gs, whereas *IMD2* transcription starts in a G-poor DNA region and is therefore favoured by low GTP pools ([@b8]; [@b7]; [@b36]; [@b20]; [@b17]). The *URA2* start choice, however, depends on a different mechanism, as upstream initiation does not occur preferentially at T\'s and is not sensitive to the abundance of uracil ([@b37]). Conversely, we found that 3 out of 10 *URA2* cDNAs produced under activating conditions started with a T, which argues against the simple idea of a selection driven by the nature of the starting nucleotide. Nevertheless, the upstream initiator is followed by an ∼60 nt T-rich domain, continued by 40 nt that are conspicuously poor in T\'s and harbour the *URA2* mRNA 5′-ends. This pattern is conserved among all *Saccharomyces* species sequenced to data (see [Supplementary data](#S1){ref-type="supplementary-material"}), and we would be surprised if it did not provide some form of UTP-sensing. Further studies are clearly needed to better understand how RNA polymerase II responds to NTP shortage, and how this response is ultimately converted into a specific control of the *IMD2*, *URA2* and *URA8* genes.

Materials and methods
=====================

Plasmids
--------

Newly constructed plasmids are listed in [Supplementary data](#S1){ref-type="supplementary-material"}. Plasmids pFL35-II, pFL36-CII (*CEN6 LEU2*) and pFL39-CII (*CEN6 TRP1*), corresponding to pFL35, pFL36 and pFL39 ([@b5]), with an extended polylinker of 90 nucleotides ([Supplementary data](#S1){ref-type="supplementary-material"}). pFL80 and pFL82 are *pURA2∷LacZ pURA2* reporters derived from pFL39-CII and pFL36-CII, respectively. They harbour a *Kpn*I--*Bam*HI--*Not*I *pURA2∷LacZ* cassette of 4392 nt. The *Kpn*I--*Bam*HI segment (1254 nt) is formed by the *TRK1--URA2* intergenic region, preceded by *GGTACC*AGCACAACGCTCTAA (the *Kpn*I site is in italics) and followed by AT*GGATCC* (*Bam*HI). It is cloned in-frame to the initiator ATG of a *Bam*HI--*Not*I *LacZ* cassette. pFL83 is pFL80 where the *LacZ* open reading frame has been replaced by a *Bam*HI--*Not*I *HIS3* (*S. cerevisiae*) cassette. As pFL80 poorly complemented *trp1* mutant strains, which overexpressed the *pURA2* promoter (due to some transcriptional interference between *LacZ* and *TRP1*), we also used pFL80-H2, a *pURA2∷LacZ* reporter with a lower *LacZ* expression. This plasmid was selected after random insertion of genomic *Hin*dIII fragments in the unique *Hin*dIII site downstream of *LacZ* ([Supplementary data](#S1){ref-type="supplementary-material"}). The *Hin*dIII fragment of pFL80-H2 corresponded to positions 7679--8251 of the *TEL1* gene and was inserted in a transcriptional orientation opposite to the one of *TRP1*.

Plasmids pFL80-KB, pFL80-BS and pFL80-CS correspond to *Kpn*I/*Bsr*GI, *Bsr*GI/*Sal*I and *Cla*I/*Sal*I deletions of pFL80, respectively. pFL80-INTΔ was precisely deleted of the DNA comprised between nucleotides −384 to −63, where 1 corresponds to the *URA2* start codon. The pFL83-upΔ2, -up6Δ and -up10Δ plasmids were obtained by error-prone amplification of the *Kpn*I--*Bam*HI cassette of pFL83, which was recombined into the original vector by co-transformation with linearised pFL83 DNA deleted of its *Bsr*GI--*Sal*I fragment. Mutant plasmids were selected on 3-aminotriazol in the presence of uracil, amplified in *Escherichia coli*, retransformed and verified for their overexpression. The corresponding *up*Δ alleles were transferred to pFL80 by *Kpn*I--*Bam*HI subcloning.

Yeast strains
-------------

Yeast mutants are listed as [Supplementary data](#S1){ref-type="supplementary-material"}. Plasmid shuffle assays were done in the presence of 5-fluoro-orotic acid to counter-select *URA3* plasmids ([@b4]). Except when stated otherwise, they were constructed in BMA64-1A and BMA64-URA3, a *URA3*^+^ revertant of BMA64-1A ([@b2]). Yeasts were grown on SD+aa, corresponding to the standard synthetic dextrose medium supplemented with histidine, tryptophan and adenine sulphate (20 mg/l), leucine and lysine (30 mg/l). In β-galactosidase assays, SD+aa was replaced by the complete synthetic medium CSM (manufactured by BIO101) supplemented with a complete set of amino acids but lacking uracil. CSM supplemented with 2 g/l of uracil (CSM+U) fully represses *URA2*, whereas adding 6-azauracil at 20 mg/l (CSM+ 6AU) fully activates *URA2*.

FL50 was obtained by inserting the integrative plasmid pFL81 (*TRP1 pURA2∷HIS3*) at the *Eco*RV site of the *trp1-1* allele in W303-1B. When grown in the presence of uracil, this strain has an increased sensitivity to 3-aminotriazol, due to the repression of its *pURA2∷HIS3* reporter. FL52 is FL50 transformed with pFL82 (*LEU2 pURA2∷LacZ*). FL-M9, M10, M13 and M23 are FL52 mutants selected from UV-irradiated cells (about 1% survival) plated for 3 days at about 4 × 10^6^ cells on leucine omission plates with uracil (2 g/l) and 50 or 100 mM of 3-aminotriazol. β-galactosidase was assayed in a loop of cells put on Whatman paper soaked in 2 ml of Z buffer ([@b25]) containing X-Gal (1 g/l) and a drop of zymolase. Dark blue clones were tested again, using freshly grown cells suspended in 0.6 ml of Z buffer and vortexed for 1 min with an equal volume of glass beads. Cells were refrigerated in an ice bath, treated with a second round of glass bead extraction, pelleted by centrifugation at 14 000 r.p.m. and tested for β-galactosidase after 10 min at 37 °C. Mutant strains with an at least fivefold increase in β-galactosidase were retained for further analysis. A fifth mutant was a *fur1* allele partly defective for UMP pyrophosphorylase, impairing the metabolic conversion of uracil into UMP.

FL51, with the *up2*Δ allele integrated on the chromosome by homologous recombination, was constructed by subcloning the *Kpn*I--*Bam*HI fragment of pFL81-up2Δ into pFL35-II. The resulting plasmid was linearised at the *Bsm*I site of the *pURA2* promoter region, to direct its integration by homologous recombination with the *pURA2* region of BMA64-URA3. The corresponding transformants harboured the *TRP1* cassette flanked by wild-type and *up2*Δ tandem copies of *pURA2*. Tryptophan auxotrophic clones spontaneously occurred by recombination between these *pURA2* copies and were selected by nystatin enrichment ([@b34]), yielding single copies of *pURA2*. Among them, *up2*Δ mutants were identified by their weak resistance to 5-fluorouracil (10^−5^ M), and were further checked by PCR amplification.

ChIP and genome-wide ChIP-chip assays
-------------------------------------

Chromatin immunoprecipitation assays were as described elsewhere ([@b11]). All experiments were performed on three independent cultures of 100 ml, harvested at an OD~600~ of 0.3--0.5. Cells were grown in SD+aa with or without uracil, or UTP-depleted by adding 200 mg/l of 6-azauracil to log-phase cells grown in SD+aa and grown for three additional doubling times. RNA polymerase II was immunoprecipitated with Dynabeads anti-mouse IgG (Dynal Biotech), using anti-CTD antibodies (8WG16), or anti-hemagglutinin A antibodies (12CA5) in the case of Rpb3-HA tagged strains. Sua7-TAP and Rad3-TAP proteins were directly immunoprecipitated on Dynabeads anti-mouse IgG. Phosphorylated variants of the RNA polymerase CTD domain were immunoprecipitated with Dynabeads anti-mouse IgM, using anti-Ser2^P^ (H5, Covance) and anti-Ser5^P^ (H14, Covance) antibodies. ChIP signals were calculated by the immunoprecipitation/input signal. The value 1.0 was arbitrarily given to the reference signal provided by amplifying the *GAL1* gene. Genome-wide ChIP assays, on the basis of three independent cultures in YPD or CSM medium for mycophenolate experiments (10 mg/l) medium, were described elsewhere ([@b14]) and were based on DNA arrays with over 40 000 oligonucleotide probes covering 12 Mb of the yeast genome ([@b11]).

RNA and transcriptome assays
----------------------------

Total RNA was extracted from three independent, exponential cultures with hot phenol and reverse-transcribed using 1 μg of total RNA, Super-Script II reverse transcriptase (Invitrogen) and random hexamers as primers. Controls without reverse transcriptase showed negligible levels of DNA contamination. DNA was quantified by real-time PCR amplification (Applied Biosytems, System SDS Software) using primers listed in [Supplementary data](#S1){ref-type="supplementary-material"}. mRNA levels are calculated as a ratio of measured mRNA and *ACT1* mRNA. The 5′-ends of *URA2* mRNAs were mapped by sequencing cDNAs obtained by the RNA ligase mediated-RACE technique (using an RLM-RACE kit from Ambion), according to the protocol provided by the manufacturer. Yeast micro-arrays were probed against total RNA extracted from three independent cultures of strains BMA64-URA3 (wild type) and FL-M9 (*rpb1-L1397S*) grown on SD+aa at 30 °C, to an OD~600~ of 0.55. cDNA synthesis, purification, indirect labelling, microarray hybridisation, scanning and analysis were done according to standard protocols ([@b35]), with two independent hybridisations for each RNA batch.
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![Transcriptional regulation of *URA2* in response to UTP shortage. (**A**) Schematic view of the *TRK1--URA2* intergenic region. The corresponding DNA was cloned as a *Kpn*I--*Bam*HI cassette to generate the pFL80 and pFL80-H2 *pURA2∷LacZ* reporter plasmids. A box denotes the 5′-UTR intron. The broken arrow corresponds to the *URA2* mRNAs 5′-ends. (**B**) β-galactosidase activities of BMA64-URA3 (WT) and FL55 (*ura8-ts ura7*Δ) grown without uracil (CSM) at 30 and 34 °C, in the presence of uracil (CSM+U), mycophenolate (CSM+MPA) and 6-azauracil (CSM+6AU). (**C**) Three independent cultures of BMA64-URA3 (WT) and FL53 (*ppr1*Δ) were exponentially grown without (−URA) or with uracil (+URA), or with 200 mg/l of 6-azauracil (+6AU). *URA1* and *URA2* mRNAs were quantified by RT--PCR, and RNA polymerase II occupancy was determined by ChIP assays, using anti-CTD antibodies (8WG16). A schematic map represents the *URA1* gene, with the oligonucleotide pairs used as primers. Position 1 corresponds to the start codon.](emboj2008165f1){#f1}

![Organisation of the *URA2* promoter region. (**A**) Deletion mutagenesis of promoter region. *LacZ* expression in BMA64-URA3 (WT) transformed with pFL80 (*pURA2∷LacZ*), pFL80-KBΔ (*Kpn*I--*Bsr*GI deletion), pFL80-BSΔ (*Bsr*GI--*Sal*I deletion) and pFL80-INTΔ (no intron). Strains were exponentially grown without (−URA) or with uracil (+URA), or with 200 mg/l of 6-azauracil (+6AU). β-galactosidase was expressed in arbitrary units ([@b25]), where 1.0 is the level measured in wild-type cells grown in CSM. Broken arrows correspond to the transcriptional initiator regions, shown in black for full-length *URA2* mRNA and in grey for short upstream untranslated RNAs ([@b37]). A canonical TATAAA box and a cluster of TCTT (UCUU) motifs (stars) are also indicated (see [Supplementary data](#S1){ref-type="supplementary-material"}). (**B**) Identification of the *URA2* 5′-end region and of an *URA2* intron. Thirteen cDNAs primed from an oligonucleotide corresponding to positions 167/188 of the *URA2* open reading frame were amplified by the RNA Ligase Mediated-RACE technique (Materials and methods). The six *URA2* start sites (underlined) fall between positions −589 and −563, containing the unique *Sal*I site (*gtcgac*). Nine cDNAs were extracted and amplified from wild-type cells (BMA64-URA3) grown without uracil (−URA), or with 200 mg/l of 6-azauracil (+6AU), and four others were prepared from FL-M9 (*rpb1-L1397S*) grown without uracil (−URA). This also confirmed the existence of an intron between positions −385 and −66 ([@b18]), but with 3′-borders corresponding to positions −63, −54 or, in one case, +12.](emboj2008165f2){#f2}

![The DNA upstream of the transcription start impairs *URA2* expression. (**A**) Schematic organisation of the *up*Δ mutations. Thick black line corresponds to the deleted DNA *up2*Δ, *up6*Δ and *up10*Δ. Stars indicate TCTT (UCUU) boxes. Broken arrows correspond to the transcriptional initiator regions as shown in [Figure 2A](#f2){ref-type="fig"}. (**B**) Effect of *up2*Δ on *pURA2∷LacZ* expression and *URA2* mRNA steady-state level. BMA64-URA3 (WT) was transformed with pFL80 or pFL80-up2Δ. β-galactosidase was tested as shown in [Figure 2A](#f2){ref-type="fig"}. *URA2* mRNA is expressed in arbitrary units ([@b25]), where 1.0 corresponds to wild-type cells grown in the absence of uracil (−URA). RT--PCR assays are based on three independent cultures of BMA64-URA3 (WT) and FL51 (*up2*Δ), grown with (+URA) or without uracil (−URA), or containing 200 mg/l of 6-azauracil (+6AU).](emboj2008165f3){#f3}

![Distribution of TFIIB, TFIIH and RNA polymerase II at the *URA2* locus. (**A**) TFIIH (Rad3-TAP) and TFIIB (Sua7-TAP) were detected by ChIP assays as described in Materials and methods. Strains D712-10C (WT *RAD3∷TAP*) and D714-5D (WT *SUA7∷TAP*) were grown on SD+aa. The schematic organisation of the corresponding DNA is presented below. Broken arrows represent the *URA2* mRNA start sites and the upstream initiator, as in [Figure 2A](#f2){ref-type="fig"}. (**B**) RNA polymerase II was immunoprecipitated with Dynabeads anti-mouse (Dynal Biotech), using anti-CTD (8WG16), anti-Ser2^P^ and anti-Ser5^P^ antibodies (Covance). Strain GR44-11C (WT) was grown on SD+aa. A schematic map indicates the oligonucleotides used as primers. (**C**) RNA polymerase II occupancy in wild-type, *ppr1*Δ and *up2*Δ. Strains GR44-11C (WT), FL53 (*ppr1*Δ) and FL51 (*up2*Δ) were grown at 30 °C on SD+aa with 2 g/l of uracil (+URA) or exposed to 200 mg/l of 6-azauracil (+6AU). ChIP signals were detected with anti-CTD antibodies (8WG16). A schematic map represents the *URA2* gene, with the oligonucleotides used as primers.](emboj2008165f4){#f4}

![Properties of Switch 1 loop mutants. (**A**) GR44-11C (WT) and D711-13B (*rpb1-L1397S*) cells spotted on SD+aa or SD+aa supplemented with mycophenolate (50 mg/l) or 6-azauracil (20 and 200 mg/l). FL53 (*ppr1*Δ) and FL51 (*up2*Δ) were used as controls. Cells were microphotographed in exponential cultures grown in SD+aa at 30 °C. (**B**) Expression of *pURA2∷LacZ*. β-galactosidase was assayed as shown in [Figure 2A](#f2){ref-type="fig"}, in strains BMA64-URA3 (WT) and FL-M9-URA3 (*rpb1-L1397S*) transformed with the pFL80 or pFL80-up2Δ *pURA2∷LacZ* reporter plasmids. (**C**) GR44-11C (WT) or YGH2 (WT), D711-13B (*rpb1-L1397S*), FL51 (*up2*Δ) and D876-10D (*rpb1-L1397S up2*Δ) were exponentially grown in CSM. Total RNA was extracted as described in Materials and methods. Steady-state levels of *URA1, URA2* and *URA3* mRNAs were quantified by RT--PCR and expressed in arbitrary units, where 1.0 corresponds to the wild-type level of *URA1* mRNA in CSM medium for *URA1* and *URA3*, and to the wild-type level of *URA2* mRNA in CSM.](emboj2008165f5){#f5}

![Organisation of the Switch 1 loop in RNA polymerase II. (**A**) Sequence alignments with yeast, archaeal and bacterial subunits. The Switch 1 loop domains ([@b12]) of Rpb1, Rpa190 and Rpc160 (*S. cerevisiae*) were aligned with the corresponding region of *M. jannaschii* (subunit A) and of the β′ subunits of *E. coli*, *Thermus aquaticus* and *Synechocystis* 6803. Amino-acid conservation is shown in red (all species), gold (Eukaryotes and Archaea) and blue (Prokaryotes only). Circles denote the mutated amino acids of *rpb1-G1388V*, *rpb1-L1397S*, *rpb1-S1401P* and *rpb1-F1402L*. (**B**) Spatial organisation of the Bridge, Trigger and Switch 1 fold in *S. cerevisiae*, *S. solfataricus* and *T. thermophilus* on the basis of PDB files 2NVZ, 2PMZ and 205I, respectively. These domains are shown on the Rpb1 sequence, with the same colour code and with numbers indicating the corresponding amino-acid positions. (**C**) Organisation of the Switch 1 loop in RNA polymerase II, using a different orientation, and showing the whole 10-subunit structure of RNA polymerase II (without Rpb4 and Rpb7). The template and non-template DNA strands and the nascent RNA are in dark green, light green and orange, respectively. A box shows the details of Switch 1 loop, underscoring the DNA-binding positions R1386 and E1403 by space-filling.](emboj2008165f6){#f6}

![RNA polymerase II occupancy in *rpb1-L1397S*. (**A**) RNA polymerase II occupancy at *ADH1* and *PYK1* in D535-4D (*RPB3∷HA*) and D535-9D (*rpb1-L1397S RPB3∷HA*). Cells were grown in SD+aa at 30 °C. RNA polymerase II was immunoprecipitated with anti-HA antibodies. A schematic map represents the oligonucleotide pairs used as primers. Position +1 corresponds to the initiator ATG. (**B**) Genome-wide ChIP assays. Three independent cultures of YGH2 (wild-type) and D711-13B (*rpb1-L1397S*) were grown in YPD at 30 °C. Chromatin was extracted and analysed as described previously ([@b11]). (**C**) Distribution of RNA polymerase II at the *URA2* locus. Data were extracted from genome-wide analysis shown in [Figure 7B](#f7){ref-type="fig"} above. The wild-type and *rpb1-L1397S* profiles are shown in grey and black, respectively. (**D**) Effect of *rpb1-L1397S*, *rpb2-P1018S* and *rpb9*Δ on RNA polymerase II occupancy at *URA2*. Experimental conditions were as shown in [Figure 7A](#f7){ref-type="fig"}. The strains used were D535-4D (*RPB3∷HA*), D535-9D (*rpb1-L1397S RPB3∷HA*), YMW304-8C (*rpb2-P1018S RPB3∷HA*) and YWM305-2D (*rpb9*Δ *RPB3∷HA*).](emboj2008165f7){#f7}

![Effect of *rpb1-1397S* on *IMD2*, *IMD3*, *ADE12*, *URA7* and *URA8*. (**A**) Enrichment of RNA polymerase II transcripts in D535-9D (*rpb1-L1397S*) compared with an isogenic wild-type obtained by complementation with pFL36-RPB1. The histogram represents median percentile ranks of Cy3/Cy5 fluorescence ratios. Data are based on three independent cultures of each strain. The *URA2*, *URA8*, *ADE12* and *IMD2-4* transcripts are individualised by arrows. (**B**) RT--PCR of individual mRNAs. GR44-11C (WT), D711-13B (*rpb1-L1397S*) and FL51 (*up2*Δ) were exponentially grown in SD+aa. Total RNA was extracted as described in Materials and methods. Individual mRNAs were quantified by RT--PCR and expressed in arbitrary units, where 1.0 corresponds to the wild-type level. (**C**) RNA polymerase II occupancy at *IMD2* and *IMD3*. Data were extracted from the genome-wide analysis shown above ([Figure 7B](#f7){ref-type="fig"}) except for *IMD2* in wild-type cells grown in CSM+MPA, taken from [@b11]. (**D**) RNA polymerase II occupancy at *URA7*, *URA8* and *ADE12*. Data were extracted from the genome-wide analysis shown above ([Figure 7B](#f7){ref-type="fig"}).](emboj2008165f8){#f8}
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